Rivermark Medical Showcases BPH Clinical Program at Major Urology Conference

According to a recent LinkedIn post from Rivermark Medical, the company participated in the EAU 2026 urology conference, where its clinical development work was featured in two sessions presented by urologist Dean Elterman. The post highlights that Rivermark’s team has been focused on developing what it describes as a one-of-a-kind treatment for benign prostatic hyperplasia (BPH) and is already engaging around future events such as AUA26 in Washington, D.C.

For investors, the visibility at a major European Association of Urology meeting suggests that Rivermark’s BPH program is progressing toward broader clinical and professional recognition, an important step for eventual commercialization in a large and growing market. The emphasis on multiple conference sessions and ongoing outreach to upcoming urology meetings may indicate an effort to build clinical advocacy and KOL support, which could be critical for reimbursement, adoption, and future fundraising or partnership opportunities if the therapy advances successfully through trials.